approval · primary record
LUMASIRAN SODIUM
FDA · NDA · 2025-04-04
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2025-04-04 |
| Approval events | 1 |
| Brand | OXLUMO |
| Sponsor | ALNYLAM PHARMS INC |
| Route | SUBCUTANEOUS |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2025-04-04 | FDA | NDA | OXLUMO | ALNYLAM PHARMS INC | SUBCUTANEOUS |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:31:20.081Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:lumasiran-sodium
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lumasiran Sodium · compound